Risk Factors and Clinical Impact of Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae

被引:253
作者
Gasink, Leanne B. [1 ,3 ,5 ]
Edelstein, Paul H. [1 ,2 ]
Lautenbach, Ebbing [1 ,3 ,4 ,5 ]
Synnestvedt, Marie [6 ]
Fishman, Neil O. [1 ,5 ]
机构
[1] Univ Penn, Sch Med, Div Infect Dis, Dept Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
[3] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA
[4] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA
[5] Univ Penn, Sch Med, Ctr Educ & Res Therapeut, Philadelphia, PA 19104 USA
[6] Univ Penn, Sch Med, Off Human Res, Philadelphia, PA 19104 USA
关键词
RESISTANT PSEUDOMONAS-AERUGINOSA; INTENSIVE-CARE UNITS; NEW-YORK-CITY; BETA-LACTAMASE; ANTIBIOTIC-RESISTANCE; FLUOROQUINOLONE USE; ACQUISITION; EMERGENCE; KPC-2; INFECTION;
D O I
10.1086/648451
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
BACKGROUND. Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae is an emerging pathogen with serious clinical and infection control implications. To our knowledge, no study has specifically examined risk factors for KPC-producing K. pneumoniae or its impact on mortality. METHODS. To identify risk factors for infection or colonization with KPC-producing K. pneumoniae, a case-control study was performed. Case patients with KPC-producing K. pneumoniae were compared with control subjects with carbapenem-susceptible K. pneumoniae. A cohort study evaluated the association between KPC-producing K. pneumoniae and in-hospital mortality. RESULTS. Fifty-six case patients and 863 control subjects were identified. In multivariable analysis, independent risk factors for KPC-producing K. pneumoniae were (1) severe illness (adjusted odds ratio [AOR], 4.31; 95% confidence interval [CI], 2.25-8.25), (2) prior fluoroquinolone use (AOR, 3.39; 95% CI, 1.50, 7.66), and (3) prior extended-spectrum cephalosporin use (AOR, 2.55; 95% CI, 1.18, 5.52). Compared with samples from other anatomic locations, K. pneumoniae isolates from blood samples were less likely to harbor KPC (AOR, 0.33; 95% CI, 0.12, 0.86). KPC-producing K. pneumoniae was independently associated with in-hospital mortality (AOR, 3.60; 95% CI, 1.87-6.91). CONCLUSIONS. KPC-producing K. pneumoniae is an emerging pathogen associated with significant mortality. Our findings highlight the urgent need to develop strategies for prevention and infection control. Limiting use of certain antimicrobials, specifically fluoroquinolones and cephalosporins, use may be effective strategies.
引用
收藏
页码:1180 / 1185
页数:6
相关论文
共 35 条
[1]   Clinical characteristics and molecular epidemiology associated with imipenem-resistant Klebsiella pneumoniae [J].
Ahmad, M ;
Urban, C ;
Mariano, N ;
Bradford, PA ;
Calcagni, E ;
Projan, SJ ;
Bush, K ;
Rahal, JJ .
CLINICAL INFECTIOUS DISEASES, 1999, 29 (02) :352-355
[2]   Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobactetiaceae [J].
Anderson, K. F. ;
Lonsway, D. R. ;
Rasheed, J. K. ;
Biddle, J. ;
Jensen, B. ;
McDougal, L. K. ;
Carey, R. B. ;
Thompson, A. ;
Stocker, S. ;
Limbago, B. ;
Patel, J. B. .
JOURNAL OF CLINICAL MICROBIOLOGY, 2007, 45 (08) :2723-2725
[3]  
[Anonymous], 2003, ALL PATIENT REFINED
[4]   Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 β-lactamases in New York City [J].
Bradford, PA ;
Bratu, S ;
Urban, C ;
Visalli, M ;
Mariano, N ;
Landman, D ;
Rahal, JJ ;
Brooks, S ;
Cebular, S ;
Quale, J .
CLINICAL INFECTIOUS DISEASES, 2004, 39 (01) :55-60
[5]   Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City -: A new threat to our antibiotic armamentarium [J].
Bratu, S ;
Landman, D ;
Haag, R ;
Recco, R ;
Eramo, A ;
Alam, M ;
Quale, J .
ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (12) :1430-1435
[6]   Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York:: Epidemiology and recommendations for detection [J].
Bratu, S ;
Mooty, M ;
Nichani, S ;
Landman, D ;
Gullans, C ;
Pettinato, B ;
Karumudi, U ;
Tolaney, P ;
Quale, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (07) :3018-3020
[7]   National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004 [J].
Cardo, D ;
Horan, T ;
Andrus, M ;
Dembinski, M ;
Edwards, J ;
Peavy, G ;
Tolson, J ;
Wagner, D .
AMERICAN JOURNAL OF INFECTION CONTROL, 2004, 32 (08) :470-485
[8]   Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States [J].
Endimiani, Andrea ;
Carias, Lenore L. ;
Hujer, Andrea M. ;
Bethel, Christopher R. ;
Hujer, Kristine M. ;
Perez, Federico ;
Hutton, Rebecca A. ;
Fox, William R. ;
Hall, Geraldine S. ;
Jacobs, Michael R. ;
Paterson, David L. ;
Rice, Louis B. ;
Jenkins, Stephen G. ;
Tenover, Fred C. ;
Bonomo, Robert A. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (07) :2680-2682
[9]   Risk factors of carbapenem-resistant Klebsiella pneumoniae infections:: a matched case-control study [J].
Falagas, Matthew E. ;
Rafailidis, Petros I. ;
Kofteridis, Diamantis ;
Virtzili, Simona ;
Chelvatzoglou, Fotini C. ;
Papaioannou, Vassiliki ;
Maraki, Sofia ;
Samonis, George ;
Michalopoulos, Argyris .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2007, 60 (05) :1124-1130
[10]   Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era? [J].
Falagas, Matthew E. ;
Bliziotis, Ioannis A. .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007, 29 (06) :630-636